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ONE SENTENCE SUMMARY: A Tribbles 2 pseudokinase small molecule screen led to the 
identification of known EGFR/HER2 inhibitors that alter the stability of TRIB2 in vitro and lead to 
rapid on-target degradation of TRIB2 in human cancer cells. 
SHORT ABSTRACT: (150 words) 
Tribbles 2 (TRIB2) is a cancer-associated pseudokinase with a diverse interactome, including the 
AKT signaling module. Substantial evidence demonstrates that TRIB2 dysregulation is important in 
multiple human tumors. The non-canonical TRIB2 pseudokinase domain contains a unique cysteine 
rich region and interacts with a peptide motif in its own C-terminal tail. We demonstrate that TRIB2 
is a target for previously described small molecule protein kinase ‘inhibitors’, which were originally 
designed to inhibit the catalytic domain of EGFR/HER2 tyrosine kinases. Using thermal-shift assays 
and drug repurposing, we classify ligands that stabilize or destabilize the TRIB2 pseudokinase 
domain. TRIB2 destabilizing agents, including the clinical inhibitor afatinib, lead to rapid and on-
target TRIB2 protein degradation in tumor cells, eliciting tractable effects on cell signaling and 
survival. Our data identifies leads for further development of TRIB2-degrading drugs and highlights 
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compound-induced TRIB2 downregulation, which might be mechanistically relevant for other 
catalytically-deficient (pseudo)kinases targeted by small molecules.  
FULL ABSTRACT: (232 words) 
A major challenge associated with biochemical and cellular analysis of pseudokinases is the lack of 
target-validated small molecule ligands with which to probe molecular function. Human Tribbles 2 
(TRIB2) is a cancer-associated pseudokinase with a diverse interactome, which includes the canonical 
AKT signaling module. There is substantial evidence that human TRIB2 is a therapeutic target in both 
solid tumors and blood cancers. The non-canonical TRIB2 pseudokinase domain contains a unique 
cysteine-rich region and interacts with a peptide motif in its own C-terminal tail, which was 
previously shown to drive interaction with cellular E3 ubiquitin ligases. In this study we demonstrate 
that TRIB2 is a target for previously described small molecule protein kinase inhibitors, which were 
originally designed to inhibit the canonical catalytic domain of the tyrosine kinases EGFR/HER2. 
Using a thermal-shift assay, we discovered TRIB2 ligands within the Published Kinase Inhibitor Set 
(PKIS), and employed a drug repurposing approach to classify compounds that either stabilize or 
destabilize TRIB2 in vitro.  Remarkably, TRIB2 destabilizing agents, including the clinical covalent 
drug afatinib, lead to rapid and on-target TRIB2 degradation in human cells, eliciting tractable effects 
on signaling and survival. Our data reveal the first drug-leads for development of TRIB2-degrading 
ligands, which will also be invaluable for unravelling the cellular mechanisms of TRIB2-based 
signaling. Our study highlights that small molecule-induced protein downregulation through drug 
‘off-targets’ might be relevant for other inhibitors that serendipitously target pseudokinases. 
ABBREVIATIONS: DSF: Differential Scanning Fluorimetry; EGFR: Epidermal Growth Factor 
Receptor; HER2: Human Epidermal Growth Factor Receptor 2; MS: Mass spectrometry; MST: 
MicroScale Thermophoresis; PKIS: Published Kinase Inhibitors Set; TRIB2: Tribbles 2; TSA: 
Thermal Stability Assay 
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INTRODUCTION:  
The human protein kinome encodes ~60 protein pseudokinases, which lack at-least one conventional 
catalytic residue, but often control rate-limiting signaling outputs within cellular networks [1]. Like 
canonical kinases, pseudokinases drive conformation-dependent signaling associated with normal 
physiology and disease [2, 3]. The human ‘pseudokinome’ includes cancer-associated signaling 
proteins such as HER3, JAK2 (JH2 domain) and TRIB2, which have historically received much less 
attention compared to their conventional, catalytically-active, counterparts even though pseudokinase 
domains represent rational targets for drug discovery [4]. Discovering or repurposing biologically 
and/or clinically-active ligands that target atypical-conformations of canonical kinases or 
pseudokinases, is an area of active research [2, 3, 5-9]. Moreover, the burgeoning pseudokinase field 
is strongly placed to benefit from the decades of research undertaken on canonical protein kinases, 
which has seen the approval of over 40 kinase inhibitors for human cancer and inflammatory diseases 
[10, 11].  
The three human Tribbles (TRIB) pseudokinases are homologues of the Drosophila melanogaster 
pseudokinase termed Tribbles, which controls ovarian border cell and neuronal stem cell physiology 
[12, 13]. Tribbles, the human TRIB1, 2 and 3 orthologues, and the related pseudokinase STK40, all 
contain a catalytically-impaired pseudokinase domain. Adaptions in the pseudokinase fold, including 
a highly unusual DC-helix, are thought to support a competitive regulatory interaction in cis with a 
unique C-terminal tail DQLVP motif [14-16]. Through a still obscure mechanism, TRIB and STK40 
function as adaptor proteins that recruit ubiquitin E3 ligases such as COP1 through direct interaction 
with the conserved C-tail peptide [14, 16], which is required for signaling and cellular transformation 
[17]. Mechanistically, Tribbles signaling outputs are controlled through the ubiquitylation and 
subsequent proteasomal destruction of Tribbles ‘pseudosubstrates’, such as vertebrate C/EBPD, 
CDC25C and Acetyl CoA carboxylase [18-20]. 
A longstanding goal in cancer research is drug-induced degradation of oncogenic proteins. Progress 
towards this objective has been transformed by the synthesis of proteolysis-targeting chimeras 
(PROTACs), which induce proteasome-dependent degradation of their targets. Multifunctional small 
molecule PROTACS often possess ligand-binding regions derived from kinase inhibitors [21, 22], and 
multiple classes of non-PROTAC kinase inhibitor also induce kinase target degradation, although 
typically at higher (micromolar) concentrations than those required for enzymatic inhibition [7]. 
Recent reports also disclose classes of covalent ligands that bind and disable Cys-containing small G-
proteins such as mutant human RAS, permitting covalent inactivation of this previously ‘undruggable’ 
oncoprotein [23, 24]. Cys residues are widespread and highly conserved in kinases [25] and the 
conservation of Cys residues both inside and outside the catalytic domain provides kinome-wide 
opportunities for exploitation using chemical biology [26]. In this context, covalent targeting 
methodologies involving compound-accessible Cys residues in kinases [8, 27-30] and pseudokinases 
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[3], have attracted significant attention for small molecule design, due to the potential for gains in 
target specificity and durability of responses, combined with tractability in experimental systems.  
Tribbles pseudokinases are implicated in a huge variety of physiological signalling pathways, often in 
the context of protein stability, but also through regulation of key modules, such as the canonical 
AKT pathway [31]. TRIB2 is also implicated in the aetiology of human cancers, including leukemias, 
melanoma, lung and liver cancer [32]. In particular, TRIB2 is a potential drug target in subsets of 
acute myeloid and lymphoid leukemia (AML and ALL), which are in urgent need of targeted 
therapeutics to help treat untargeted or drug-resistant patient populations [33]. TRIB2 protein levels 
have also been linked to drug-resistance mechanisms, where an ability to modulate the pro-survival 
AKT signaling module underlies a central regulatory role in cell proliferation, differentiation, 
metabolism and apoptosis [31, 34-38].  
In this paper, we report that the low-affinity TRIB2 ATP-binding site [39] is druggable with small 
molecules previously recognized as ATP-competitive pan-EGFR/HER2 kinase inhibitors. 
Biochemical analysis confirms the existence of distinct ligand-induced TRIB2 conformations and a 
compound screen identifies known EGFR/HER2 inhibitors that stabilize or destabilize TRIB2 in vitro. 
TRIB2 ligands include the clinical breast cancer therapeutic lapatinib/Tykerb [40] and the approved 
irreversible electrophilic covalent inhibitors afatinib/Giotrif [41, 42] and neratinib/Nerlynx [43, 44]. 
In the case of these two destabilizing agents, binding leads to uncoupling of the pseudokinase domain 
from its own C-terminal tail. Consistently, cellular afatinib exposure leads to rapid TRIB2 degradation 
driven by an interaction with the Cys-rich pseudokinase domain, which interferes with AKT signaling 
and decreases cell survival in a TRIB2-expressing leukemia model. The availability of target-
validated ligands that act as rapid TRIB2 pseudokinase down-regulators through a direct effect on the 
pseudokinase, represents a new way to evaluate TRIB2 physiology and cell signaling. It might also 
have a broader impact on the rapidly developing pseudoenzyme field [45], where the concept of 
pseudokinase destabilization or elimination by targeted kinase ‘inhibitors’ [7] has a number of 
potentially useful applications.  
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RESULTS: 
Analysis of human TRIB2 using a thermal stability assay 
Human TRIB2 differs from TRIB1 and TRIB3 in the pseudokinase domain due to a Cys-rich region 
at the end of the E3 Lys-containing motif, which extends into the truncated DC-helix in the N-lobe 
(Figure 1A, top).  We developed a Differential Scanning Fluorimetry (DSF) assay [46-48] to examine 
thermal stability of full-length (1-343) His-tagged TRIB2 protein, and compared it to full-length 
cAMP-dependent protein kinase (PKAc) catalytic subunit, or full-length Cys 104 Tyr TRIB2, in 
which Cys 104 was replaced with the Tyr residue conserved in human TRIB1 and TRIB3 (Figure 
1A). Proteins were purified to homogeneity (Figure 1A, bottom) and thermal stability based on 
unfolding profiles were determined for each protein (reported as a Tm value, Figure 1B). As 
previously demonstrated [39], TRIB2 (Tm = ~39 °C) was much less thermostable than the canonical 
protein kinase (PKA, Tm = 46.3 °C). Remarkably, single substitution of Cys 104 with Tyr induced a 
potent stabilization of TRIB2, with the Tm value increasing to ~49 °C, comparable to that of human 
TRIB1 [14], suggesting an important structural role for this unique Cys residue in TRIB2 (un)folding 
dynamics. To confirm that recombinant TRIB2 binds to a known physiological target, we 
demonstrated that GST-tagged TRIB2 interacted with a marked preference for catalytically inactive 
(non Thr 308-phosphorylated) AKT1 in vitro (Figure 1C). Consistent with a functional regulatory 
interaction between TRIB2 and AKT in cells [49], transient overexpression of Tet-inducible FLAG-
tagged TRIB2 in HeLa cells led to a marked increase in endogenous AKT phosphorylation at the 
hydrophobic motif (Ser 473, Figure 1D), an established marker for AKT catalytic activity and the 
downstream generation of a cellular anti-apoptotic signal [50]. 
A DSF screen for TRIB2 ligands using a kinase inhibitor library 
The ability of full-length recombinant human TRIB2 to bind to ATP in the presence of EDTA [39, 47] 
confirms that a vestigial nucleotide-binding site is present within the pseudokinase domain. Moreover, 
our previous work established that an analogue-sensitive (Phe 190 Gly) TRIB2 variant could be 
stabilized by ‘bumped’ pyrimidine analogues in vitro [39].  In order to discover drug-like ligands for 
WT full-length TRIB2, we screened the Published Kinase Inhibitor Set (PKIS), a collection of high-
quality class-annotated kinase inhibitors [51]. We enforced cut off values of ~'Tm = <-2 °C and >+3.5 
°C (therefore eliminating ~97% of the library) to define ‘hit’ compounds that possessed the ability to 
either destabilize or stabilize TRIB2 respectively in a thermal stability assay (TSA) at a 1:4 
TRIB2:compound molar ratio (Figure 1E and Supplementary Table 1). The top ‘stabilizing’ 
compound identified was GW693881A, a dual EGFR/HER2 thienopyrimdine inhibitor exhibiting a 
'Tm of +4.7 °C. The top ‘destabilizing’ compound was GW804482X, a thiophene polo-like kinase 
(PLK) inhibitor that induced a 'Tm of - 3.4 °C (Figure 1E, red symbols). Interestingly, most of the top 
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stabilizing and destabilizing compounds belong to well-known ATP-competitive pyrimidine or 
quinazoline EGFR/HER2 chemotypes (Supplementary Figure 1) [52-54], suggesting broad structural 
cross-reactivity between TRIB2 and the ligand-responsive EGFR/HER2 conformation. To build upon 
these findings, we screened a larger panel of known dual EGFR/HER2 inhibitors (Supplementary 
Figure 2), and established that the clinical type I EGFR/HER2 inhibitors TAK-285 and lapatinib also 
stabilized TRIB2 in vitro (Figure 1F).  Interestingly, the ATP-competitive covalent EGFR/HER2 
inhibitors afatinib, neratinib and osimertinib (but not the unrelated covalent Bruton’s Tyrosine Kinase 
(BTK) inhibitor ibrutinib or the Type I EGFR-specific inhibitors erlotinib or gefitinib) destabilized 
TRIB2, similar to the PLK inhibitor GW804482X (Figure 1F) and the dual EGFR/HER2 inhibitor 
GW569530A (Supplementary Figure 1). Compound effects were caused through TRIB2 targeting in 
the TSA, because no shift was elicited when PKAc was compared in a side-by-side counter-screen, 
using dasatinib as a positive control (Supplementary Figure 3). Interestingly, the preclinical PLK 
inhibitors BI2536 and BI6727 (volasertib) had no discernible effect on TRIB2 stability in this assay, 
in contrast to GW804482X, a PLK inhibitor originally isolated in the screen (Figure 1F).  
Afatinib, neratinib and osimertinib are all covalent (type IV) inhibitors of canonical EGFR/HER2 
tyrosine kinase targets, interacting irreversibly with a conserved Cys residue in the ATP-binding site 
[55, 56]. As show in Figure 1G, the stabilization of TRIB2 by lapatinib, and the destabilization of 
TRIB2 by all three covalent EGFR/HER2 inhibitors, occurred in a dose-dependent manner. 
Interestingly, a Cys 104 Tyr TRIB2 mutant was no longer destabilized by either afatinib or neratinib, 
but remained ‘sensitive’ to lapatinib TAK-285 and GW804482X based on thermal-shifting (Figure 
1H). Importantly, none of the latter compounds contain an electrophilic ‘warhead’ required for 
covalent interaction (Supplementary Figure 2). Cys 104 Tyr TRIB2 was also insensitive to thermal 
shift in the presence of ATP and EDTA (Figure 1H and Supplementary Figure 4). These data suggest 
that Cys 104 is both a key determinant for ATP binding and TRIB2 interaction with covalent kinase 
inhibitors, which induce TRIB2 destabilization in vitro.   
Mechanistic analysis of TRIB2 structural stability and TRIB2 ligand binding 
Structural analysis of TRIB1 by X-ray crystallography and small angle X-ray scattering led to the 
proposal of an in cis self-assembly model, whereby the unique C-terminal tail region, which contains 
the conserved ‘DQLVP’ motif, binds directly to the pseudokinase domain adjacent to the short DC-
helix of TRIB1 [14, 15]. We exploited DSF to investigate whether this mechanism is also relevant in 
TRIB2 by generating a series of truncated proteins. These lacked either the N-terminal extension, 
which was predicted to be disordered by both I-TASSER [57] and VSL2 [58], the C-terminal tail, or 
both N and C-terminal domains. We also generated a triple point mutant in which the ‘DQLVP’ tail 
motif, which is required for TRIB1 and TRIB2 cellular transformation in vivo [17], was mutated to 
‘AQLAA’ (Figure 2A). Full-length (1-343) TRIB2 and TRIB2 lacking the N-terminal domain (TRIB2 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/305243doi: bioRxiv preprint first posted online Apr. 20, 2018; 
 7 
54-343) both exhibited similar Tm values of 39-40 °C (Figure 2B). In contrast, deletion of the C-tail 
(TRIB2 1-318) markedly changed TRIB2 stability, with Tm values falling to ~37°C, diagnostic of a 
destabilized TRIB2 conformation (Figure 2B). Mutation of DQLVP to AQLAA further destabilized 
TRIB2, inducing a Tm value of ~36 °C (Figure 2B). Using this panel of recombinant TRIB2 proteins, 
we measured the relative effects of kinase inhibitors on TRIB2 stability. Consistent with a lack of 
effect on compound interactions, deletion of the TRIB2 N-terminal region had no effect on 'Tm 
values induced by any of the compounds. Removal of the C-tail region (54-318 and 1-318 mutants) 
completely abolished afatinib and neratinib-induced TRIB2 destabilization, but had a negligible effect 
on GW804482X binding (Figure 2C). Consistently, destabilization by afatinib was also completely 
abolished in the AQLAA triple mutant, whereas neratinib effects were reduced by >50%. Notably, 
neither the destabilizing effect of GW804482X, nor the stabilizing effects of lapatinib or TAK-285 
differed between any of the TRIB2 proteins evaluated. These results suggest a destabilizing 
mechanism induced by covalent EGFR/HER2 ligands through displacement of the TRIB2 C-tail, a 
unique feature of Tribbles pseudokinases [12, 14].  
To evaluate whether the EGFR/HER2 ligand afatinib targeted the unique Cys residues in the TRIB2 
pseudokinase domain (Figure 1A), we performed mass spectrometry (MS) analysis to evaluate protein 
modification. As shown in Supplementary Figure 5A, incubation of TRIB2 with a 5-fold molar excess 
of afatinib led to covalent afatinib interaction with Cys 96. A doubly charged chymotryptic product 
ion representing the TRIB2-derived DISC96Y:afatinib peptide adduct at m/z 543.2 (Supplementary 
Fig. 5A) and the isotopic ratios of the 35Cl or 37Cl-containing peptide ions unequivocally confirmed 
Cys 96 as a site of TRIB2 binding (Supplementary Figure 5B). Having confirmed an intact mass for 
recombinant full-length TRIB2 of 43,587.09 Da, very similar to the predicted mass of 43,587.22 Da 
(Supplementary Figure 5C), we were also able to ascertain that pre-incubation with afatinib generated 
covalent adducts containing predominantly either 1 or 2 molecules of afatinib. There was also some 
evidence for tri and tetra-modified TRIB2 adducts (Supplementary Figure 5D). We next examined 
afatinib interaction with TRIB2 by Microscale Thermophoresis (MST), a biophysical technique for 
quantification of reversible biomolecular interactions [59]. This confirmed an interaction between 
afatinib and fluorescent NTA-coupled His-TRIB2, which could be fitted to a reversible binding event 
with a Kd value of ~16 PM (Supplementary Figure 6). Moreover, it suggested initial (reversible) 
binding of the ATP-competitive afatinib ligand [60, 61] prior to subsequent formation of a covalent 
TRIB2 adduct(s) (Supplementary Figure 5). Finally, we evaluated the potential interaction of afatinib 
and neratinib with a modelled TRIB2 pseudokinase domain [12] using AutoDock Vina [62]. Blind 
docking of the covalent inhibitors employing the entire TRIB2 homology model revealed a putative 
binding pocket formed by residues in the vestigial C-helix, including Cys 96, the P-loop and the 
activation loop. We assessed potential binding modes for afatinib and neratinib using a covalent 
docking approach [63], in which the compounds were flexibly docked to the identified pocket by 
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covalently linking the electrophilic warhead to the sulfhydryl Cys. Covalent docking revealed 
structurally and energetically-feasible binding modes for both afatnib and neratinib bound to Cys 96. 
The most commonly sampled poses are shown in Supplementary Figure 7.  
To validate the functional importance of Cys residues for afatinib binding, we examined the 
interaction of this compound with TRIB2 in which two Cys amino acids were mutated to non-thiol 
containing Ser residues. Individual or combined mutation of Cys 96 and Cys 104 to a Ser residue had 
no effect on the thermal profile (Tm) of the purified TRIB2 proteins (Figure 2D), in contrast to the 
highly stabilizing effect of a Tyr at position 104 (Figure 1B and Supplementary Figure 4). However, 
individual or joint mutation of Cys 96 and Cys 104 to Ser severely blunted the destabilizing effect of 
afatinib and neratinib on TRIB2, in contrast to the non-covalent TRIB2 ligand GW804482X or the 
EGFR/HER2 stabilizing compounds lapatinib and TAK-285 (Figure 2E). Taken together, these 
findings confirm that several EGFR/HER2 compounds bind to TRIB2 through Cys96 and/or Cys104. 
Evaluation of TRIB2 ligands in human cells 
To evaluate the effects of various kinase inhibitors on TRIB2 in living cells, we generated a 
polyclonal TRIB2 antibody and an isogenic stable HeLa cell line expressing Tet-inducible FLAG-
tagged human TRIB2. Polyclonal TRIB2 antibodies were equally efficient at recognising recombinant 
His-FLAG-TRIB2 and cellular FLAG-TRIB2 as a commercial monoclonal FLAG antibody 
(Supplementary Figure 8A). We also constructed a stable HeLa cell line expressing low levels of 
inducible FLAG-TRIB2 (Supplementary Figure 8B). We estimated that ~1 ng of TRIB2 was 
expressed in 40 Pg of whole cell lysate in the presence of Tet, by comparing known amounts of 
recombinant His-FLAG-TRIB2 protein (Supplementary Figure 8B). 
To quantify effects of TRIB2 expression on canonical signaling in model cells, we first evaluated 
AKT phosphorylation. As shown in Figure 3A, AKT became phosphorylated in stable HeLa cells 
after serum stimulation in the absence of Tet. Tet-induced TRIB2 expression led to the appearance of 
a TRIB2 doublet (phosphorylation confirmed in the upper band by lambda phosphatase treatment, 
Supplementary Figure 9), and a marked increase in the extent and duration of AKT phosphorylation at 
Ser 473. Using this HeLa cell model, we next evaluated the effects of small molecule inhibitors on 
TRIB2 signaling, by comparing a panel of in vitro TRIB2 destabilizing ligands discovered by DSF in 
vitro (afatinib, neratinib and osimertinib) with a series of control compounds. Brief (4h) exposure of 
TRIB2-expressing cells to afatinib led to a specific decrease in TRIB2 protein expression. All of the 
compounds evaluated are EGFR or EGFR/HER2 signaling pathway inhibitors, and we confirmed they 
all blocked ERK phosphorylation at these concentrations (Figure 3B); any unique effects of drugs in 
this panel are therefore likely to be ‘off-target’ to EGFR/HER2. We next incubated cells for 
increasing lengths of time with afatinib. A rapid, time-dependent, elimination of TRIB2 protein was 
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evident when cells were exposed to this drug, in contrast to DMSO controls in which TRIB2 protein 
accumulated over time (Figure 3C), as expected [18]. To evaluate intracellular interaction between 
TRIB2 and kinase inhibitors, we exposed HeLa cells expressing Tet-inducible FLAG-TRIB2 to each 
compound, and quantified TRIB2 thermal stability in the cell extracts using a cellular TSA 
(Supplementary Figure 10) [64]. Consistently, FLAG-TRIB2 was destabilized more rapidly than 
DMSO and erlotinib-treated controls in the presence of afatinib, becoming undetectable in extracts 
heated to 45 °C (Supplementary Figures 10A and 10B). This was distinct from lapatinib, which 
partially stabilized exogenous TRIB2 in cell extracts, consistent with in vitro analysis (Figure 1F).  
Afatinib interacts with TRIB2 through a biochemical Cys-based mechanism, so we generated isogenic 
Tet-inducible Cys 96 Ser or Cys 96/104 Ser TRIB2 mutant stable cell lines and evaluated the effects 
of afatinib on exogenous TRIB2 stability. As shown in Figure 4A, afatinib (but not lapatinib or TAK-
285) induced dose-dependent loss of TRIB2 in WT-TRIB2 cells, which was partially prevented by 
mutation of Cys 96 to Ser, and completely abolished in double Cys-expressing cells (quantified in 
Figure 4A, right panels), demonstrating unequivocally that afatinib binds to TRIB2 in these cells. 
Furthermore, afatinib (but not TAK-285 or erlotinib) treated WT-TRB2 cells exhibited a marked 
decrease in AKT Ser 473 phosphorylation, and this effect was abrogated in double Cys-expressing 
mutant cells (Figure 4B). Importantly, afatinib, TAK-285 and erlotinib all blocked ERK 
phosphorylation in WT and C96/104S-TRIB2 isogenic lines, consistent with ‘on-target’ inhibition of 
their common target EGFR (Figure 4B).  
To investigate the mechanism of TRIB2 destabilization by afatinib, we added the drug to WT-TRIB2 
expressing HeLa cells in the presence of the proteasome inhibitor MG132, which partially rescued 
TRIB2 degradation after both rapid and prolonged exposure to afatinib (Figure 4C). This finding is 
consistent with previously reported proteasome-dependent TRIB2 turnover [65]. We further evaluated 
this mechanism using a range of MG132 concentrations and the clinical proteasome inhibitor 
bortezomib (Figure 4D) [20]; under both conditions, afatinib-mediated destabilization of TRIB2 was 
decreased. This effect was in contrast to afatinib-induced TRIB2 destabilization, which was still 
observed in the presence of non-specific inhibitors of autophagy (AICAR) and lysosomal degradation 
(chloroquine) (Figure 4D). Our observations are in line with published findings, which suggest that 
TRIB2 fate is dependent upon turnover by the ubiquitin proteasome system (UPS) in human cancer 
cells [18, 66]. Of further interest, the (non-covalent) TRIB2-destabilizing ligand GW804482X isolated 
from our screen (Figure 1), did not induce TRIB2 degradation in cells after a 4-hour incubation 
period, in contrast to proteasome-dependent degradation induced by the same concentration of 
afatinib (Supplementary Figure 11). 
High levels of TRIB2 expression drive AML in vivo by inhibiting myeloid differentiation and 
promoting proliferation [17, 34]. However, endogenous TRIB2 expression has only previously been 
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analysed in a few cell types, in large part due to a lack of reliable TRIB2 reagents. Using our TRIB2 
antibody, we evaluated endogenous expression of TRIB2 in the clinically-relevant U937 AML cell 
model (Figure 5A), and established that acute (4 h) exposure to afatinib, but not lapatinib or erlotinib, 
decreased TRIB2 protein levels in a dose-dependent manner (Figure 5A). Consistent with their ability 
to inhibit EGFR signaling, all three compounds completely blocked ERK phosphorylation. We next 
established dose-dependent effects on both TRIB2 expression and AKT Ser 473 phosphorylation in 
afatinib-treated U937 cells (Figure 5B). Importantly, these effects were tightly correlated with 
apoptotic induction of caspase 3 cleavage, but only at afatinib concentrations that also induced TRIB2 
degradation and concomitant loss of AKT Ser 473 phosphorylation (Figure 5B). To determine the 
impact of afatinib treatment on U937 cell viability we quantified cellular cytotoxicity after 72 h 
exposure (Figure 5C). Afatinib (and neratinib) reduced cell viability with sub-micromolar IC50 values, 
whereas EGFR inhibitors erlotinib and gefitinib and the dual EGFR/HER2 inhibitor TAK-285, were 
10-20 fold less effective when compared side-by-side (Figure 5C). As these compounds did not 
induce TRIB2 destabilization, AKT activation or caspase 3 activation, our data suggest that the 
cellular TRIB2-destabilizing ligands afatinib and neratinib possess an enhanced ability to kill AML-
derived cells [49].  
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DISCUSSION: 
A ligand-targetable regulatory mechanism in human TRIB2 
It is believed that rate-limiting signaling outputs are often controlled by non-enzymatic components, 
exemplified by mechanistically-related families of pseudoenzymes such as pseudokinases [45]. In the 
present study, we sought to target cancer-associated TRIB2 with a small molecule; initially the 
intention was to establish the validity of this approach for this class of pseudokinase, but subsequently 
we were also able to evaluate the effects of TRIB2 compound engagement in intact human cells. To 
discover TRIB2 ligands, we exploited an unbiased TRIB2 thermal shift assay [39, 47], and identified 
multiple chemical classes of dual EGFR/HER2 (but not monovalent EGFR) inhibitors. One group of 
(ATP-competitive) kinase inhibitor induced stereotypical (positive) thermal shifts in TRIB2, 
consistent with binding in the atypical TRIB2 nucleotide-binding site [47]. A second group of 
chemical ligands induced TRIB2 destabilization, which although initially unexpected, could be 
explained mechanistically by a compound-induced effect in which the TRIB2 pseudokinase domain 
became uncoupled from its own C-tail region. A similar mechanism has been proposed to explain 
thermally-distinct conformers that exist in TRIB1, which shares ~70% identity with TRIB2 in the 
pseudokinase domain and a very similar C-tail motif [15]. Deletion of the TRIB1 C-tail also leads to 
the destabilization of the TRIB1 pseudokinase domain compared to full-length TRIB1 [14], similar to 
destabilizing effects observed for TRIB2 1-318 and 54-318 deletion mutants and an AQLAA mutant. 
These data allow us to propose that pseudokinase-domain docking to the C-terminal tail generates a 
thermally-stable conformation in both TRIB1 and TRIB2, and in the case of TRIB2, that this dynamic 
interaction can be targeted with ATP-competitive covalent kinase inhibitors, which induce a structural 
pseudokinase conformation associated with decreased stability in vitro.  
How do covalent EGFR/HER2 inhibitors target TRIB2? 
We focused our studies on electrophilic type IV kinase inhibitors, since they were likely to bind to 
TRIB2 via a covalent mechanism, which is amenable to comparative chemical and mutational 
analysis [30, 67]. Using a combination of techniques, we confirmed that at-least two highly conserved 
TRIB2 Cys residues are targets of the ATP-dependent tyrosine kinase inhibitor afatinib [68] in vitro. 
Both TRIB2 Cys-residues are uniquely located between the ATP-binding E3-Lys residue (Lys90 in 
TRIB2) and the very short DC-helix. In most canonical kinases, including EGFR family members, 
positioning of this helix is critical for catalysis and switching between inactive and active enzyme 
conformations, both of which can be targeted with small molecules [69]. Dynamic helix positioning is 
known to be generally important for interactions with kinase inhibitors, some of which recognise 
‘inactive’ conformations in kinases in which the DC helix adapts to permit compound binding, as 
established for HER2 [70]. The conformation of the flexible C-helix relative to the ATP binding P-
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loop also creates an allosteric binding pocket in canonical kinases such as ERK1/2, which can be 
targeted with selective non ATP-competitive inhibitors such as SCH772984 that possess slow off-rate 
kinetics [71]. In TRIB2, a unique disposition of Cys residues (Figure 1A) makes it vulnerable to 
destabilization by the EGFR/HER2 covalent inhibitors afatinib, neratininb and osimertinib in vitro, 
which all undergo Michael addition to a conserved Cys residue in the roof of the ATP-binding site of 
EGFR-related tyrosine kinases (Cys 797 in EGFR, Cys805 in HER2 and Cys803 in HER4) [61]. 
Interestingly, afatinib also demonstrates low, but detectable, affinity for the ATP-binding 
pseudokinase domain of HER3 [72, 73], which possesses a Ser residue (Ser 794) at the equivalent 
residue to Cys 797 of EGFR, and assumes a pseudo ‘active’ catalytic conformation, despite 
possessing exceptionally low kinase activity [73]. In the absence of a high-resolution TRIB2 
pseudokinase crystal structure, we do not yet know the conformation(s) relevant for small molecule 
interaction, although the TRIB2 N-lobe has both shared and distinct features (notably TRIB2 Cys 
104) compared to TRIB1 [14]. This is reflected biochemically by marked differences in the ability of 
TRIB2 to bind to ATP, which likely predisposes it to targeting by EGFR/HER2 kinase inhibitors 
(Supplementary Figure 7). Interestingly, none of the EGFR family members possess a Cys residue in 
the C-helical region conserved in TRIB2, and the overall identity between HER2 and TRIB2 in the 
(pseudo)kinase domain is very low indeed (~22%). We therefore believe that our discovery of TRIB2 
binding to covalent inhibitors such as afatinib owes as much to the unique availability of reactive Cys 
residues adjacent to an allosteric pocket in the TRIB2 pseudokinase domain as to the (presumably) 
lower affinity for the vestigial ATP-binding site. Our work builds on previous studies in which 
pseudokinase domains have been targeted with small molecule kinase ‘inhibitors’ [3]. Examples 
include the ligand TX1-85-1 [8], which binds covalently to Cys721 (inducing HER3 degradation in 
cells) and recently described non-covalent JAK2 JH2 (pseudokinase) domain ligands, confirmed 
through structural analysis [74, 75]. 
In the course of compound screening, we discovered that unrelated classes of ATP-competitive dual 
EGFR/HER2 ligands, including thienopyrimidines [54] and thiazolylquinazolines [53] also bound to 
TRIB2 in vitro. In contrast to destabilization (a feature of covalent TRIB2 ligands) these compounds 
stabilize TRIB2 in vitro, similar to lapatinib and the pyrrolo[3,2-d]pyrimidine EGFR/HER compound 
TAK-285, which can bind to HER2 in an active-like conformation [76]. This might be equivalent to 
the thermostable TRIB2 generated by compound binding or after Cys 104 Tyr substitution. Moreover, 
evidence for a stabilized TRIB2:lapatinib complex was also established in cell extracts using CETSA 
(Supplementary Figure 10). Of relevance, the ATP-competitive ligands lapatinib and TAK-285 did 
not induce TRIB2 degradation in cells. However, previous studies demonstrated that lapatinib can 
deprive HER2 of an interaction with the Hsp90-Cdc37 system, leading to time-dependent HER2 
degradation at micromolar concentrations [77]. Interestingly, like HER2, the cellular mechanism by 
which TRIB2 stability is regulated is proteasome-based (Figure 4), and we speculate that an afatinib-
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induced conformational change might induce TRIB2 ubiquitination, or negatively regulate interaction 
with an unknown stabilizing factor(s), similar to the effects of Hsp90 inhibitors towards the stability 
of Cdc37 kinome clients [78-80]. Consistently, TRIB2 is itself regulated by ubiquitination [18, 65, 
66], and future work will evaluate TRIB2 binding to small molecules with dynamic changes in TRIB2 
ubiqutination.  
The future: Targeting TRIB2 in cancer and beyond 
The finding that TRIB2 stabilizing and destabilizing cell permeable ligands can be discovered by 
simple DSF profiling is an important advance for the evaluation of compounds that target this, and 
other, catalytically-deficient pseudokinases. The interaction of TRIB2 with both covalent and non-
covalent clinical ligands confirms our original hypothesis, which stated that the TRIB2 pseudokinase 
represents a bona fide drug target [5]. We found that unique Cys residues in TRIB2 make it 
vulnerable to known families of small molecule kinase inhibitors that were originally developed as 
nanomolar covalent inhibitors of the tyrosine kinases EGFR and HER2. Such dual-targeting suggests 
shared features between signaling-relevant conformations in the ATP-site of both TRIB2 and 
EGFR/HER2, which generates reciprocal compound interactions. Conserved Cys residues in the 
atypical TRIB2 C-helical region most likely represent an additional form of selectivity filter, which 
permits targeting of TRIB2 by covalent classes of EGFR/HER2 inhibitor at micromolar 
concentrations in cells. Based on this mechanism, a lack of equivalent Cys residues in other 
pseudokinases, including the related TRIB1 and TRIB3, likely prevents them from interaction with 
covalent ligands such as afatinib.  
Using a chemical genetic approach, we provide strong evidence that afatinib induces on-target effects 
through TRIB2 stability and AKT signaling in human cancer cells. Importantly, cellular signalling 
modulated by afatinib was prevented by mutation of two unique TRIB2 Cys residues, confirming a 
meaningful TRIB2 drug interaction in cells.  Drug interaction was also validated by DSF, MS, MST 
and by employing in-cell TSA (CETSA) approaches with exogenous TRIB2. Finally, we established 
that afatinib (and neratinib) exhibit sub-micromolar toxicity in the human AML model cell line U937, 
where they are 10-20 fold more effective at cell killing compared to equipotent EGFR/HER2 or 
EGFR inhibitors [72], which do not degrade TRIB2 but still block ERK activation. U937 cells have 
previously been shown to be hypersensitive to TRIB2 siRNA knock-down [65], strengthening the 
case that the TRIB2 pseudokinase is rate-limiting for cell survival in this context. Experimental ‘on-
target’ effects of covalent TRIB2-destablising agents were confirmed using chemical genetics and a 
Cys-mutant TRIB2 pseudokinase allele, similar to classical ‘drug-resistance’ approaches developed 
for compound target validation in the kinase inhibitor field [81-84].   
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CONCLUSION: 
Our work demonstrates that covalent EGFR/HER2 inhibitors such as afatinib possess TRIB2 
degrading-activity in human cells at micromolar concentrations, in a similar range to those reported 
for other destabilizing kinase inhibitors, including the covalent EGFR/HER2 drug neratinib [85]. 
Although we cannot rule out the simultaneous dual effects of afatinib on both TRIB2 and ERK/AKT 
phosphorylation contributing to cellular phenotypes, we provide clear evidence that TRIB2-binding is 
required for TRIB2 destabilization and AKT regulation in cells. Should an appropriate concentration 
of drug permit a direct TRIB2 interaction, an ‘off-target’ TRIB2-dependent phenotype might therefore 
be relevant to compound efficacy (or drug side-effects) in patient groups exposed to covalent 
EGFR/HER2 inhibitors. Many severe side effects of drugs are only detected after long-term clinical 
use, potentially leading to their withdrawal [86], and covalent drugs have the potential to accumulate 
to relatively high concentrations in cells. Interestingly, toxic side-effects such as diarrhea and 
vomiting induced by the EGFR/HER2 inhibitors lapatinib [87] and afatinib [88] are well-established 
in clinical patient cohorts. Based on the mechanistic studies reported here, it will be interesting to 
develop ELISA-based procedures to quantify effects of these drugs on TRIB2 protein stability in 
clinical samples obtained from drug-exposed patients, as part of broader proteomics approaches to 
establish all the intracellular targets of these compounds. Our study also provides impetus for 
generating improved (ideally TRIB2-specific) covalent ligands that induce TRIB2 degradation at even 
lower (sub-micromolar) concentrations, ideally by synthesising compounds in which the effects of 
eliminating or preserving EGFR/HER2 inhibition can be compared side-by-side. In the latter case, 
simultaneous elimination of TRIB2 and inhibition of the ERK-signaling pathway could be a 
polypharmacological asset, especially if TRIB2-dependent drug-resistance in tumor cells [38, 49] can 
be modulated by EGFR/HER2 inhibition. Taken together, our data establish a new paradigm for the 
pharmacological evaluation of agents that interfere with TRIB2-based signaling, and raise the 
intriguing possibility that dual EGFR/HER2 inhibitors might be repurposed as TRIB2-degrading 
agents in biological and clinical contexts. This information might also be exploited in the future for 
targeting a variety of TRIB2-overexpressing solid [89, 90] and haematological [20, 65] tumors. 
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MATERIALS AND METHODS: 
Chemicals, reagents, antibodies and TRIB2 small molecule screen 
Tetracycline and doxycycline, MG132, AICAR and chloroquine were purchased from Sigma. 
Afatinib, neratinib, osimertinib, ibrutinib, erlotinib, lapatinib, TAK-285, BI2536, BI6727, gefitinib 
and bortezomib were purchased from LC laboratories or Selleck. Total AKT, pSer 473 AKT, pThr 
308 AKT, total ERK1/2, dual pThr 202/pTyr 204 ERK1/2, cleaved Caspase 3 and D-tubulin 
antibodies were purchased from New England Biolabs and employed as previously described [50, 91]. 
6His-HRP and α-FLAG antibodies were purchased from Sigma, GAPDH antibody was purchased 
from Proteintech and a polyclonal rabbit α-TRIB2 antibody was raised towards a unique N-terminal 
human TRIB2 sequence and affinity purified prior to evaluation with recombinant TRIB2 and a 
variety of human cellular extracts.  
The PKIS chemical library (designated as SB, GSK or GW compounds) comprises 367 ATP-
competitive kinase inhibitors, covering ~30 chemotypes (~70% with molecular mass <500 Da and 
clogP values <5) that were originally designated as ATP-competitive inhibitors of 24 distinct protein 
kinase targets, including multiple EGFR and HER2 tyrosine kinase classes [51]. Compounds were 
stored frozen as 10 mM stocks in DMSO. For initial screening, compounds were pre-incubated with 
TRIB2 for 10 minutes and then employed for DSF, which was initiated by the addition of fluorescent 
SYPRO Orange. For dose-dependent thermal-shift assays a compound range was prepared by serial 
dilution in DMSO, and added directly into the assay to the appropriate final concentration. All control 
experiments contained 2% (v/v) DMSO, which had essentially no effect on TRIB2 stability.   
Cloning, Site Directed Mutagenesis and recombinant protein production  
pET30 6His-TRIB2 (and various deletion or amino acid substitution constructs, including an N-
terminal FLAG-tagged TRIB2, termed His-FLAG-TRIB2), and pET30a 6His-PKAc, which encodes 
catalytically-active cAMP-dependent protein kinase domain, have been described previously [39, 48]. 
Full length TRIB2 was also cloned into pOPINJ to generate a His-GST-TRIB2 encoding construct for 
GST pull-down assays. Protein expression was induced in BL21(DE3) pLysS bacteria with 0.4 mM 
IPTG, and after overnight growth at 18°C, proteins were purified to near homogeneity using an initial 
affinity step (immobilised metal affinity chromatography (IMAC) or glutathione-sepharose 
chromatography) followed by size exclusion chromatography (16/600 Superdex 200) in appropriate 
buffers. Ser 473 Asp 6His-AKT1 (DU1850, amino acids 118-470), either active (PDK1-
phosphorylated to a specific activity of 489 U/mg) or inactive, were purchased from the DSTT 
(University of Dundee), and stored at -80°C prior to analysis. Site directed mutagenesis was 
performed as previously described [92], using KOD Hot Start DNA polymerase and appropriate 
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mutagenic primer pairs (sourced from IDT). All plasmids were Sanger-sequenced across the entire 
coding regions to confirm expected codon usage. 
Differential Scanning Fluorimetry (DSF) 
Thermal-shift assays were performed using an Applied Biosystems StepOnePlus Real-Time PCR 
instrument using a standard DSF procedure previously developed and validated for the analysis of 
kinases [46, 48] and pseudokinases [47]. Proteins were diluted in 20 mM Tris/HCl (pH 7.4), 100 mM 
NaCl and 1 mM DTT to a concentration of 5 μM and then incubated with the indicated concentration 
of compound in a total reaction volume of 25 μL, with final concentration of 2% (v/v) DMSO. 
SYPRO Orange (Invitrogen) was used as a fluoresecence probe. The temperature was raised in 
regular 0.3 °C intervals from 25°C to 95°C. Compound binding experiments were assessed in 
duplicate and then reported relative to DMSO controls. 
Mass Spectrometry analysis of TRIB2 afatinib binding 
To evaluate TRIB2 binding in vitro, afatinib was incubated for 15 min with purified 6His-TRIB2 at a 
1:10 molar ratio, then denatured with 0.05 % (w/v) RapiGest SF (Waters, UK) and digested with 
chymotrypsin (1:20 protease:protein (w/w) ratio) for 16 h at 25 °C. RapiGest hydrolysis was induced 
by the addition of triflouroacetic acid (TFA) to 1 % (v/v), incubated at 37 °C for 1h. Insoluble product 
was removed by centrifugation (13, 000 x g, 20 min).  Reversed-phase HPLC separation was 
performed using an UltiMate 3000 nano system (Dionex) coupled in-line with a Thermo Orbitrap 
Fusion Tribrid mass spectrometer (Thermo Scientific, Bremen, Germany). 500 fmol digested peptides 
were loaded onto the trapping column (PepMap100, C18, 300 μm × 5 mm), using partial loop 
injection, for 7 min at a flow rate of 9 μL/min with 2% (v/v) MeCN, 0.1% (v/v) TFA and then 
resolved on an analytical column (Easy-Spray C18 75 μm × 500 mm, 2 μm bead diameter column) 
using a gradient of 96.2% A (0.1% (v/v) formic acid (FA)): 3.8% B (80% (v/v) MeCN, 0.1% (v/v) 
FA) to 50% B over 35 min at a flow rate of 300 nL/min. MS1 spectra were acquired over m/z 400 – 
1500 in the orbitrap (60 K resolution at 200 m/z). Data-dependent MS2 analysis was performed using 
a top speed approach (cycle time of 3 s), using higher-energy collisional dissociation (HCD) and 
electron-transfer and higher-energy collision dissociation (EThcD) for fragmentation, with product 
ions being detected in the ion trap (rapid mode). Data were processed using Thermo Proteome 
Discoverer (v. 1.4) and spectra were searched in MASCOT against the E. coli IPI database with the 
added sequence of full-length 6His-TRIB2 (1-343). Parameters were set as follows: MS1 tolerance of 
10 ppm, MS/MS mass tolerance of 0.6 Da, oxidation of methionine and afatanib binding at cysteine as 
variable modifications. MS2 spectra were interrogated manually.  
To evaluate the interaction between afatinib and intact TRIB2 protein, TRIB2 was incubated with 
afatinib as above, and then desalted using a C4 desalting trap (Waters MassPREP™ Micro desalting 
column, 2.1 × 5 mm, 20 μ m particle size, 1000 Å pore size). TRIB2 was eluted with 50 % (v/v) 
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MeCN, 0.1 % (v/v) formic acid. Intact TRIB2 mass analysis was performed using a Waters nano 
ACQUITY Ultra Performance liquid chromatography (UPLC) system coupled to a Waters SYNAPT 
G2. Samples were eluted from a C4 trap column at a flow rate of 10 µL/min using three repeated 0-
100 % acetonitrile gradients. Data was collected between 400 and 3500 m/z and processed using 
MaxEnt1 (maximum entropy software, Waters Corporation).  
 
TRIB2 modeling and compound docking 
A structural model of human TRIB2 kinase (UniProt ID: Q92519) containing the C-terminal tail 
(residues 42-343) was built, as described previously [12] using the crystal structure of TRIB1 (pdb: 
5CEM) as the template. The N-terminal tail was not modelled since it was predicted to be disordered. 
The modeled TRIB2 structure was energy minimized using the Rosetta Relax protocol [93] and the 
model with the lowest energy score from 100 potential solutions was used for docking. The chemical 
structures of afatinib (CID 10184653) and neratinib (CID 9915743) were retrieved from PubChem. 
Both compounds were independently docked using AutoDock Vina [62] with an exhaustiveness of 
1000, rigid body, and a full protein search space. A binding pocket formed between P-loop, C-helix 
and the activation loop was the most frequently sampled site during blind docking. Compounds were 
docked to this putative docking site using the flexible side-chain covalent docking method 
implemented in Autodock [94]. In brief, the enamide group of each compound was covalently linked 
to the sulfhydryl group of Cys 96 and the rest of the compound was treated as a rigid side-chain to 
explore favorable binding poses, the vast majority of which converged on the same binding pocket. 
Each run generated 500 binding poses, which were visualized using PyMOL. 
 
MicroScale Thermophoresis  
A Monolith NT.115 instrument (NanoTemper Technologies GmbH) was employed for MST analysis. 
His-TRIB2 was initially labelled with a NanoTemper labelling kit; the fluorescent red dye NT-647 
was coupled via NHS chemistry to the N-terminal His-tag, placing the fluorophore away from the 
pseudokinase domain. For MST, the reaction was performed in 20 mM Bicine pH 9.0, 100 mM NaCl, 
5% glycerol, 0.05% Tween-20 and 2 % (v/v) DMSO. Fluorescent TRIB2 (~5 PM) was kept constant 
in the assay, while final afatinib concentration was titrated between 1 nM and 50 PM. Near-saturation 
binding was achieved, allowing for an affinity to be estimated for the reversible interaction of afatinib 
with the fluorescent TRIB2.  
Cell lines and reagents 
Flp-In T-Rex parental HeLa cells (Invitrogen) were cultured in DMEM with 4 mM L-glutamine, 10 % 
(v/v) Foetal Bovine Serum (FBS), Penicillin and Streptomycin (Gibco) as described [81]. To engineer 
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Tetracycline (Tet)-controlled expression of FLAG-tagged full length TRIB2 in human Flp-In T-REx 
cell lines, the host plasmid pcDNA5/FRT/TO, encoding full length TRIB2 sequences (or appropriate 
amino acid substitution(s)), with a single N-terminal FLAG tag (40 Pg DNA per 10 cm dish of cells) 
were co-transfected with pOG44 Flp-Recombinase Expression Vector using lipofectamine. Cells that 
had successfully integrated the FLAG-tagged TRIB2 sequence were stably selected with 200 μg/mL 
Hygromycin B, according to the manufacturer’s instructions. Tet was added at a final concentration of 
1 Pg/ml to medium in order to induce FLAG-TRIB2 expression. For transient transfection, 50% 
confluent HeLa cells were transfected with 40 Pg DNA per 10 cm dish for 48 h prior to lysis.  
For serum starvation, stable HeLa cells were grown until ~60% confluent in complete medium 
(+FBS), washed with PBS, and replaced with serum-free DMEM for 16 h. Cells were then incubated 
with DMEM containing 10% (v/v) FBS ± 1 Pg/ml Tet for 16 h, followed by addition of appropriate 
inhibitor for 4h. Cells were then lysed, and whole cell extracts generated with modified RIPA buffer. 
Non-adherent AML-derived human U937 cells (which express high levels of endogenous TRIB2 
protein) were supplied by Dr Karen Keeshan, University of Glasgow and were cultured as previously 
described [20].    
MTT cytotoxicity assay 
U937 cells were seeded in a 96 well plate at a concentration of 0.2 x 106 cells/mL, 18 hours prior to 
compound addition, which was performed in triplicate, with all experiments including a final 
concentration of 0.1% DMSO (v/v). To quantify U937 cell viability, metabolic activity was assessed 
72 h after compound exposure using an MTT assay, as described previously [95]. Briefly, Thiazolyl 
blue tetrazolium bromide was dissolved in PBS and added to cells at a final concentration of 0.25 
mg/mL and incubated at 37 °C for 3 hours. The reaction was stopped by the addition of 50 μL of 
acidified 10% SDS, followed by reading of absorbance at 570 nm. Viability was defined relative to 
DMSO-containing controls incubated for the same period of time. 
Immunoblotting and CETSA 
HeLa and U937 whole cell lysates were generated by lysis in modified RIPA buffer (50 mM Tris–HCl 
pH 7.4, 1 % (v/v) NP-40, 1 % (v/v) SDS, 100 mM NaCl, 100 nM Okadaic acid) in the presence of 
protease and phosphatase inhibitors, and sonicated briefly to shear DNA prior to analysis. Samples 
were boiled for 5 min in sample buffer (50 mM Tris pH 6.8, 1% SDS, 10% glycerol, 0.01% 
Bromophenol Blue, 10 mM DTT). Subsequently, between 40 and 120 Pg of total protein was resolved 
by SDS–PAGE followed by transfer onto nitrocellulose membrane (BioRad). After blocking in pH 
7.4), primary and secondary antibodies were incubated in the same condition, and proteins were 
detected using HRP-conjugated antibodies and ECL reagent. Immunoblots were quantified using 
ImageJ software, as previously described [91]. For lambda phosphatase treatment, 40 Pg FLAG-
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TRIB2 expressing stable cell extracts in lysis buffer without SDS and phosphatase inhibitors were 
incubated with 10 ng of purified O-phosphatase for 30 min at 37°C prior to processing for western 
blotting. 
For in-cell CETSA we employed a previously published procedure [96]. Briefly, stable HeLa cells 
were incubated with Tet for 16h to induce expression of FLAG-TRIB2, and at ~90% confluence, were 
incubated with 0.1% (v/v) DMSO or 100 PM of the indicated compound for 1h. Intact cells were 
isolated by trypsinization (1 min) and resuspended in PBS, and then aliquoted into individual PCR 
tubes prior to heating at the indicated temperature in a PCR thermal cycler for 3 min. Cells were then 
placed on ice for 2 min and lysed by sonication, prior to centrifugation at 16,000 x g for 20 minutes at 
4°C. The soluble lysate was analysed for the presence of FLAG-TRIB2 and D-tubulin by 
immunoblotting. 
Statistical analysis 
All experimental procedures were repeated in at least 3 separate experiments (unless stated otherwise) 
and data are expressed as the mean ± standard deviation, where appropriate. When applied, statistical 
significance was defined as a p-value of ≤0.05, either using either a Students t-test or analysis of 
variance (ANOVA).  
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FIGURE LEGENDS: 
Figure 1. Full-length TRIB2 is a target for protein kinase inhibitors in vitro 
(A) Sequence alignment of human TRIB1, TRIB2 and TRIB3, highlighting Cys-rich residues (red) in 
the TRIB2 pseudokinase domain.  Recombinant proteins employed for in vitro analysis. 5 μg of the 
indicated purified proteins were resolved by SDS-PAGE. (B) Thermal denaturation profiles of 
recombinant proteins. A representative unfolding profile is shown.  Tm values (±SD) were obtained 
from 3 separate fluorescence profiles, each point assayed in duplicate. (C) The ability of GST-TRIB2 
to interact with active (PDK1-phosphorylated) or inactive (non PDK1-phosphorylated) Ser 473 Asp 
AKT1 was assessed by GSH-sepharose pull-down followed by immunoblotting. PDK1 
phosphorylated Ser 473 Asp AKT is also phosphorylated on Thr 308 (right panel), but binds very 
weakly to TRIB2. (D) Transient transfection of Tet-inducible FLAG-TRIB2 leads to increased AKT 
phosphorylation on Ser 473. (E) TRIB2 DSF screen using PKIS. 5 µM His-TRIB2 was employed for 
all DSF analysis. ΔTm values were calculated for each compound. Scattergraph of data highlights a 
wide variety of compounds that either stabilize or destabilize TRIB2 in vitro. Cut off values of >3.5 
°C and < 2°C were used to designate ‘hits’. (F) Comparative DSF analysis of clinical and preclinical 
kinase inhibitors as potential TRIB2 ligands. LAP=lapatinib, TAK=TAK-285, AFA=afatinib, 
NER=neratinib, OSI=osimertinib, IBR=ibrutinib, ERL=erlotinib, GEF=gefitinib. (G) Dose-dependent 
analysis of thermal shifts induced by clinical TRIB2 ligands. Compounds were tested at 5, 10, 20, 40, 
80 and 160 µM. (H) Profiling of TRIB2 and C104Y with selected inhibitors by DSF.  
Figure 2. TRIB2 thermal stability is modulated through Cys binding to covalent inhibitors  
(A) Schematic cartoon of TRIB2 with domain boundaries numbered and cysteine residues highlighted 
(red). SDS-PAGE of 5 μg of recombinant TRIB2 proteins. (B) Thermal denaturation profiles of 5 μM 
WT-TRIB2 (amino acids 1-343), three truncated variants and an AQLAA triple-point mutant. 
Representative curves for each protein and average Tm values (±SD) are shown. (C) Thermal shift 
analysis of TRIB2 deletion and AQLAA proteins measured in the presence of a panel of compounds 
(20 PM). The change in Tm value ('Tm) is reported from duplicate experiments, each performed in 
triplicate and the chemical structures of each compound are shown for comparison. AFA=afatinib, 
NER=neratinib, LAP= lapatinib, ERL=erlotinib. (D) Thermal denaturation profiles for purified 
TRIB2 and Cys 96 Ser, Cys 104 Ser and Cys 96/104 Ser proteins. (E) Thermal shift analysis of 
TRIB2 Cys-mutated proteins measured in the presence of a pane 
l of compounds (20 µM). The change in Tm value ('Tm) is reported from triplicate experiments.  
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Figure 3: Afatinib promotes rapid degradation of FLAG-TRIB2 in an inducible HeLa cell 
model 
(A) Uninduced (-Tet) or Tetracycline-induced (+Tet) HeLa cells containing a stably integrated 
FLAG-TRIB2 transgene were serum starved for 12 h prior to the addition of serum, and lysed at the 
indicated times. Whole cell extracts were blotted with FLAG antibody to detect FLAG-TRIB2, pSer 
473 AKT. Total AKT and total GAPDH served as loading controls. (B) A selection of clinically 
approved kinase inhibitors, including dual EGFR/HER2 and EGFR-specific compounds, were added 
to Tet-induced cells at a final concentration of 10 μM. Stable cells were induced to express FLAG-
tagged TRIB2 with tetracycline for 16h prior to inhibitor treatment for 4 hours. AFA=afatinib, 
NER=neratinib, OSI=osimertinib, IBR=ibrutinib, LAP=lapatinib, ERL=erlotinib, GEF=gefitinib. 
Whole cell extracts were immunoblotted with FLAG, pERK, ERK or GAPDH antibodies. (C) Stable 
HeLa cells were incubated with Tet for 16h, and then incubated with DMSO or 10 µM afatinib (AFA) 
prior to lysis at the indicated time. Whole cell extracts were immunoblotted with FLAG or GAPDH 
antibodies.   
Figure 4. On-target degradation of TRIB2 by afatinib: Cys 96/104 Ser TRIB2 is resistant to 
degradation  
(A) The indicated concentration of afatinib, lapatinib or TAK-285 (10 PM) was incubated for 4 h with 
isogenic stable HeLa cells expressing FLAG-tagged WT-TRIB2, Cys 96 Ser or Cys 96/104 Ser 
TRIB2 (induced by Tet exposure for 16h). After lysis, whole cell extracts were immunblotted with the 
indicated antibodies. FLAG-TRIB2 levels were quantified after exposure to 10 µM afatinib relative to 
DMSO controls using ImageJ densitometry software, with a representative experiment shown 
(significance assessed using data from three independent experiments and students t-test p=0.019 and 
p=0.0066 relative to FLAG-tagged WT-TRIB2). (B) WT and Cys 96/104 Ser stable HeLa cell lines 
were subjected to a serum block-and-release protocol. Subsequently, the indicated compounds (10 
PM) were added for 4 h prior to cell lysis and immunoblotting with the indicated antibodies. 
AFA=afatinib, ERL=erlotinib. (C) FLAG-tagged TRIB2 expressing HeLa cells were incubated with 
(0.1% v/v) DMSO or 10 μM afatinib, in the presence or absence of 10 PM MG132 for 4 hours (left) 
or at the indicated time points (right) prior to lysis and processing for immunoblotting. (D) FLAG-
TRIB2 expressing stable cells were incubated with the indicated concentration of MG132 in the 
presence or absence of 10 μM afatinib for 4 h prior to cell lysis and immunoblotting (left) or for 1h 
with 10 PM bortezomib (BOR), 1 mM AICAR (AIC) or 50 PM Chloroquine (CLQ) prior to the 
addition of afatinib (AFA, 10 PM) for an additional 4 h, prior to lysis and immunoblotting with the 
indicated antibodies.  
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Figure 5. Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase-3 
cleavage and U937 cytotoxicity 
(A) Endogenous TRIB2 is destabilized in human U937 cells in a dose-dependent manner after a 4 h 
exposure to afatinib (AFA). Cells were incubated with either 0.1% (v/v) DMSO, the indicated 
concentrations of afatinib, or 10 μM lapatinib (LAP), 10 μM erlotinib (ERL) or 10 PM of the 
proteasome inhibitor bortezomib (BOR) for 4 h prior to lysis and immunoblotting of endogenous 
TRIB2, pERK or cleaved caspase 3. GAPDH served as a loading control. (B) Endogenous TRIB2 is 
destabilized after exposure to afatinib for 24h, concomitant with reduced AKT phosphorylation at Ser 
473. After cell collection and lysis, whole cell extracts were immunoblotted with the indicated 
antibodies. AKT and GAPDH served as loading controls and ERL and BOR were used at 10 μM. (C) 
The cytotoxicity of a panel of TRIB2-destabilsing ligands (afatinib, AFA and neratinib, NER) were 
compared to EGFR inhibitors or the TRIB2 stabilizer TAK-285 (TAK). MTT assays were performed 
after 72 h compound exposure, with bortezomib (BOR) employed as a positive control. IC50 values 
(nM ± SD) are derived from 3 independent experiments performed in triplicate. Statistical analysis 
confirmed a significantly-different (~20-fold increase) in cytotoxicity for AFA exposure when 
compared together with TAK-285, ERL and GEF (p=0.0006) and also significantly different 
cytotoxic effects of BOR, AFA and NER when compared to the EGFR inhibitor erlotinib (p=<0.01). 
Supplementary Figure 1. Discovery of multiple PKIS compounds as TRIB2 ligands 
Dual EGFR/HER2 kinase inhibitors from three distinct chemical chemotypes present in the PKIS 
library were analysed by DSF using His-TRIB2 in a thermal shift assay. TRIB2 was screened with a 
4-fold molar excess of each compound (20 µM). ΔTm values were calculated for each condition, 
determined from fitting the Boltzmann equation. 10 mM ATP with 1mM EDTA (stabilization) and 
the TRIB2 thiophene ligand GW804482X (destabilization) were employed as controls. The chemical 
structures of class-specific PKIS compounds are also presented. 
Supplementary Figure 2. Chemical structure of pre-clinical and clinical compounds evaluated 
in this study 
Eleven compounds are shown, including in vitro TRIB2 stabilizing agents such as lapatinib and TAK-
285 and TRIB2 destabilizing compounds, such as afatinib, neratinib and osimertinib, all of which 
have previously been designated as dual EGFR/HER2 inhibitors. For covalent compounds, the 
electrophilic acrylamide group is shown in red. Erlotinib and gefitinib are potent (nM) clinical EGFR 
inhibitors, whereas BI2536 and BI6727 are potent (nM) PLK1-3 inhibitors. The thiophene TRIB2 
destabilizer GW804482X (a PLK inhibitor) is included for comparison. 
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Supplementary Figure 3. Validation of DSF assay using a PKAc counter-screen  
Recombinant His-PKAc stability was analysed in the presence of a panel of dual EGFR/HER2 or 
EGFR inhibitors (final concentration 160 PM), confirming a lack of binding. The PKA stabilizing 
compound dasatinib (160 PM) was employed as a positive control. Data from two experiments (±SD) 
for triplicate assays are shown. 
Supplementary Figure 4. Loss of ATP-binding induced by C104Y mutation in TRIB2 
Thermal denaturation profiles of full length WT-TRIB2 (1-343) or C104Y TRIB2 (1-343) proteins 
assessed in the presence or absence of 10 mM ATP, 1mM EDTA. A representative unfolding profile 
is shown for each.  Tm values (±SD) were calculated from 3 separate experiments, each assayed in 
duplicate. 
Supplementary Figure 5. MS-based analysis of the covalent TRIB2:afatinib complex 
MS2 spectra generated by HCD of chymotryptic peptides derived from 5 µM full length His-tagged 
TRIB2 (1-343) incubated with 20 µM afatinib for 15 minutes. (A) The doubly charged ion at m/z 
543.2 confirms covalent binding of afatinb to Cys96 in the diagnostic Asp-Ile-Ser-Cys96-Tyr 
tetrapeptide derived from chymotrypsin. (B) The isotopic distribution for the 543.2 m/z ion precisely 
matches the theoretical isotopic distribution for an ion containing chlorine isotopes 35Cl and 37Cl, 
which are present in the spectrum due to the chlorofluro-benzyl moiety present in afatinib. (C) Intact 
mass spectrum for purified His-TRIB2, indicating a calculated molecular mass of 43,588.38 Da, 
compared to a predicted mass of 43,587.09. (D) Intact mass spectrum for purified TRIB2 pre-
incubated with afatinib for 15 minutes at 20°C.  The TRIB2 spectrum was dominated by peaks 
corresponding to intact TRIB2 covalently bound to either 0, 1 or 2 afatinib molecules, although up to 
4 molecules of afatinib could be detected, with the number of covalent afatinib molecules increasing 
as a function of TRIB2 exposure time.  
Supplementary Figure 6. Microscale Thermophoresis (MST) assay 
MST analysis of the His-TRIB2 and afatinib interaction in solution demonstrates a Kd value of ~16 
PM for non-covalent reversible binding, a pre-requisite for formation of a covalent bond. 
Supplementary Figure 7. Molecular docking analysis 
TRIB2 binding pose solutions for covalently bound afatinib or neratinib were visualized using 
PyMOL. The positions of Cys96 relative to the conserved E3 Lys (Lys 90) in TRIB2 are highlighted. 
Supplementary Figure 8. A new TRIB2 antibody for quantitative analysis of TRIB2 expression 
levels and stability 
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(A) The indicated amount of purified His-FLAG-TRIB2 and a HeLa cell extract containing transiently 
expressed FLAG-TRIB2 were used for immunoblotting with FLAG antibody (top), or side-by-side 
comparison with rabbit polyclonal TRIB2 antibody (bottom). (B) Analysis of FLAG-TRIB2 
expression levels in stable HeLa cells in the presence or absence of Tetracycline (Tet). Known 
amounts of His-FLAG-TRIB2 were employed for quantification using FLAG antibody. 
Supplementary Figure 9. Analysis of TRIB2 dephosphorylation in cell extracts 
FLAG-TRIB2 expression was induced with Tet for 16h, and 40 Pg of appropriate whole cell lysates 
were treated with 10 ng lambda phosphatase for 1h revealing the presence of a slower-migrating, 
phosphorylated population of FLAG-TRIB2 in the cell extract. 
Supplementary Figure 10. TRIB2-binding to afatinib induces destabilization relative to DMSO 
in a whole cell thermal shift assay (CETSA) 
(A) Cells were grown to 90% confluency and treated with either DMSO or 100 μM of the indicated 
compounds for 1 h. Cells were subsequently collected and re-suspended in PBS. The re-suspended 
cells were sub-aliquoted into PCR tubes and heated in a series of 5 ⁰C increments for a total of 3 
minutes at each temperature between 40 to 70 ⁰C. The cells were subsequently lysed by sonication, 
centrifuged for 20 minutes at 18,000 g and analysed by western blot for either FLAG-TRIB2, alpha 
tubulin or 10 ng of His-FLAG-TRIB2. A representative experiment is shown (B) Densitometry 
analysis of CETSA experiment. TRIB2 levels (confirmed by gel migration relative to 10 ng 
recombinant His-FLAG-TRIB2) were normalised relative to unheated DMSO controls. Similar results 
were seen in an independent experiment.    
Supplementary Figure 11. Lack of effect of the non-covalent TRIB2 destabilizing ligand 
GW804482X on TRIB2 stability in stable HeLa cells 
FLAG-TRIB2-expression was induced with Tet for 24h, and cells were subsequently exposed for a 
further 4h to 10 PM GW804482X or 10 PM afatinib (AFA) in the presence or absence of 10 PM 
MG132. Cells were then lysed and processed for western blotting with FLAG or GAPDH antibodies. 
Supplementary Table 1. PKIS compound screening data for full-length TRIB2 
Data were obtained from duplicate DSF assays containing 5PM His-TRIB2 and 20 PM compound. 
n=2. Mean 'Tm values reported ± SD.  
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Supplementary Table 1 
 
Plate position Compound code ΔTm 1 ΔTm 2 average st.dev 
JMP-A1 SB-630812 -0.3 -0.27 -0.285 0.015 
JMP-A2 GW831091X -0.09 0 -0.045 0.045 
JMP-A3 GW700494X 2.83 2.06 2.445 0.385 
JMP-A4 GW461104B 1.2 1.51 1.355 0.155 
JMP-A5 GW796920X -0.12 0.07 -0.025 0.095 
JMP-A6 GW632046X 0.6 0.43 0.515 0.085 
JMP-A7 GW627834A 1.27 1.71 1.49 0.22 
JMP-A8 GSK561866B -0.03 0.24 0.105 0.135 
JMP-A9 GW352430A 0.21 0.25 0.23 0.02 
JMP-A10 SB-734117 0.63 0.64 0.635 0.005 
JMP-B1 GW620972X -0.93 -0.19 -0.56 0.37 
JMP-B2 SB-686709-A 0.1 0.13 0.115 0.015 
JMP-B3 GW578748X 0.29 0.13 0.21 0.08 
JMP-B4 GW572399X 1.81 2.06 1.935 0.125 
JMP-B5 GSK2163632A -2.96 -0.38 -1.67 1.29 
JMP-B6 GSK953913A -0.01 0.22 0.105 0.115 
JMP-B7 GSK180736A 0.27 0.32 0.295 0.025 
JMP-B8 SB-264866 0.32 0.29 0.305 0.015 
JMP-B9 GW809897X 1.63 1 1.315 0.315 
JMP-B10 SB-361058 0.44 0.47 0.455 0.015 
JMP-C1 GW829055X 1.43 1.68 1.555 0.125 
JMP-C2 GW434756X -0.12 0.11 -0.005 0.115 
JMP-C3 GSK237700A -0.36 -0.55 -0.455 0.095 
JMP-C4 GW577921A 0.77 0.03 0.4 0.37 
JMP-C5 GW621970A 0.3 0.36 0.33 0.03 
JMP-C6 SB-741905 0.06 0.22 0.14 0.08 
JMP-C7 SB-736290 0.11 0.03 0.07 0.04 
JMP-C8 SB-742865 1.01 0.83 0.92 0.09 
JMP-C9 GW874091X 0.27 0.26 0.265 0.005 
JMP-C10 SB-738561 -1.22 0.34 -0.44 0.78 
JMP-D1 GW829115X 0.05 0.28 0.165 0.115 
JMP-D2 GW856804X 0.96 1.15 1.055 0.095 
JMP-D3 GW833373X 1.05 0.91 0.98 0.07 
JMP-D4 GW796921X -0.02 0.28 0.13 0.15 
JMP-D5 GSK586581B 0 0.21 0.105 0.105 
JMP-D6 SB-390527 0.24 0.42 0.33 0.09 
JMP-D7 GSK571989A -0.33 0.05 -0.14 0.19 
JMP-D8 GW784684X 3.58 2.88 3.23 0.35 
JMP-D9 GSK204925A 0.22 0.72 0.47 0.25 
JMP-D10 SB-236687 0.45 -0.93 -0.24 0.69 
JMP-E1 GW829906X 0.52 1.29 0.905 0.385 
JMP-E2 GW813360X 0.04 0.15 0.095 0.055 
JMP-E3 GW680908A 1.37 1.33 1.35 0.02 
JMPE4 SKF-62604 -0.11 -0.07 -0.09 0.02 
JMP-E5 GSK1023156A 0.77 0.24 0.505 0.265 
JMP-E6 SB-751399 0.16 0.6 0.38 0.22 
JMP-E7 GW574783B 1.59 2.69 2.14 0.55 
JMP-E8 GW641155B 0.52 0.52 0.52 0 
JMP-E9 GW301789X 0.89 0.95 0.92 0.03 
JMP-E10 GW607049B 3.48 2.93 3.205 0.275 
JMP-F1 GSK620503A 0.1 -0.36 -0.13 0.23 
JMP-F2 GW569530A -2.56 -1.87 -2.215 0.345 
JMP-F3 SB-264865 -2.97 0.2 -1.385 1.585 
JMP-F4 GSK319347A 0.39 0.6 0.495 0.105 
JMP-F5 SB-739452 0.47 0.4 0.435 0.035 
JMP-F6 GSK711701A 0.14 0.65 0.395 0.255 
JMP-F7 GW768505A 1.31 1.14 1.225 0.085 
JMP-F8 SB-814597 0.35 0.46 0.405 0.055 
JMP-F9 GW837331X 3.16 1.88 2.52 0.64 
JMP-F10 SB-678557-A 0.57 0.5 0.535 0.035 
JMP-G1 GW775608X 0.12 0.32 0.22 0.1 
JMP-G2 GI261520A 1.58 0.81 1.195 0.385 
JMP-G3 SB-245392 -0.19 0.09 -0.05 0.14 
JMP-G4 GSK317315A 0.43 0.23 0.33 0.1 
JMP-G5 GW817396X 0.08 0.38 0.23 0.15 
JMP-G6 GW785804X 0.1 0.43 0.265 0.165 
JMP-G7 SB-732881-H 0.03 0.41 0.22 0.19 
JMP-G8 GSK1173862A 1.27 1.6 1.435 0.165 
JMP-G9 GW301888X 0.53 0.64 0.585 0.055 
JMP-G10 GW843682X 0.66 0.42 0.54 0.12 
JMP-H1 GW405841X 1.25 1.24 1.245 0.005 
JMP-H2 SB-409513 0.07 0.19 0.13 0.06 
JMP-H3 GSK619487A 0.03 0.07 0.05 0.02 
JMP-H4 GW410563A 0.07 0.27 0.17 0.1 
JMP-H5 GW784752X 0.27 0.4 0.335 0.065 
JMP-H6 SKF-86002 0.25 0.32 0.285 0.035 
JMP-H7 SB-376719 0.34 0.33 0.335 0.005 
JMP-H8 SB-223133 0.24 0.29 0.265 0.025 
JMP-H9 GW708893X 0.54 0.04 0.29 0.25 
JMP-H10 GW759710A 0.79 0.7 0.745 0.045 
JOJ-A1 GW416469X -1.26 -0.97 -1.115 0.145 
JOJ-A2 SKF-86055 -0.71 0.09 -0.31 0.4 
JOJ-A3 SB-682330-A -1.14 -1.04 -1.09 0.05 
JOJ-A4 SB-242719 -0.55 -0.85 -0.7 0.15 
JOJ-A5 SB-333612 0.18 -0.13 0.025 0.155 
JOJ-A6 GSK1030061A -0.41 -0.95 -0.68 0.27 
JOJ-A7 GSK1030059A -0.6 -0.58 -0.59 0.01 
JOJ-A8 GW799251X 1.05 -0.19 0.43 0.62 
JOJ-A9 GW832467X 0.2 0.51 0.355 0.155 
JOJ-A10 GW296115X 2.67 3.85 3.26 0.59 
JOJ-B1 GW830263A -0.27 -0.11 -0.19 0.08 
JOJ-B2 GSK1751853A -0.32 -0.43 -0.375 0.055 
JOJ-B3 GW643971X 0.84 0.3 0.57 0.27 
JOJ-B4 SB-614067-R 0.48 -0.55 -0.035 0.515 
JOJ-B5 GW694590A 3.6 3.3 3.45 0.15 
JOJ-B6 SB-278538 -1.06 -1.31 -1.185 0.125 
JOJ-B7 SB-390523 -0.53 -0.06 -0.295 0.235 
JOJ-B8 GSK200398A -0.55 -0.29 -0.42 0.13 
JOJ-B9 GW829877X -0.19 0.17 -0.01 0.18 
JOJ-B10 GW435821X 0.63 0.58 0.605 0.025 
JOJ-C1 GSK938890A -1.42 -3.46 -2.44 1.02 
JOJ-C2 GW445015X 0.1 -0.52 -0.21 0.31 
JOJ-C3 GW853609X 3.48 2.86 3.17 0.31 
JOJ-C4 SB-400868-A -0.44 -0.56 -0.5 0.06 
JOJ-C5 SB-739245-AC -0.25 -0.88 -0.565 0.315 
JOJ-C6 SB-226879 -0.65 -0.72 -0.685 0.035 
JOJ-C7 GSK1030062A -0.62 -0.7 -0.66 0.04 
JOJ-C8 GW300657X 0.35 -0.26 0.045 0.305 
JOJ-C9 SB-633825 -1.34 -2.17 -1.755 0.415 
JOJ-C10 GSK1030058A 0.38 0.44 0.41 0.03 
JOJ-D1 GW810372X -0.31 0.57 0.13 0.44 
JOJ-D2 GW627512B -0.33 0 -0.165 0.165 
JOJ-D3 SB-360741 -0.12 -0.5 -0.31 0.19 
JOJ-D4 GW580509X -0.16 -0.25 -0.205 0.045 
JOJ-D5 GW631581B 1.1 -0.12 0.49 0.61 
JOJ-D6 GSK1000163A -3.2 0.18 -1.51 1.69 
JOJ-D7 GW703087X 3.01 3.59 3.3 0.29 
JOJ-D8 GW869810X 1.31 1.88 1.595 0.285 
JOJ-D9 GW780159X -0.66 -0.55 -0.605 0.055 
JOJ-D10 SB-239272 0.31 -0.27 0.02 0.29 
JOJ-E1 GW612286X -2.41 -0.83 -1.62 0.79 
JOJ-E2 GW284408X -1.45 -1.17 -1.31 0.14 
JOJ-E3 GW450241X -1.05 -0.9 -0.975 0.075 
JOJ-E4 GSK300014A 2.08 4.08 3.08 1 
JOJ-E5 GW770220A -0.97 -0.67 -0.82 0.15 
JOJ-E6 GW785974X -0.56 -0.72 -0.64 0.08 
JOJ-E7 GW828525X 1.55 2.82 2.185 0.635 
JOJ-E8 GW406108X -0.66 1.04 0.19 0.85 
JOJ-E9 GW804482X -3.41 -3.63 -3.52 0.395 
JOJ-E10 GSK299115A 0.02 0.93 0.475 0.455 
JOJ-F1 GW290597X -0.76 -0.81 -0.785 0.025 
JOJ-F2 GW644007X -0.84 0.26 -0.29 0.55 
JOJ-F3 GW831090X -0.17 -0.05 -0.11 0.06 
JOJ-F4 SB-409514 -0.72 -0.56 -0.64 0.08 
JOJ-F5 GW794726X -0.13 0.17 0.02 0.15 
JOJ-F6 GW827099X 0.98 1.08 1.03 0.05 
JOJ-F7 GW827106X -0.05 0.11 0.03 0.08 
JOJ-F8 GW846105X 0.7 1.77 1.235 0.535 
JOJ-F9 SB-738482 0.94 1.32 1.13 0.19 
JOJ-F10 GW827396X 2.68 3.19 2.935 0.255 
JOJ-G1 SB-253228 -2.45 -0.28 -1.365 1.085 
JOJ-G2 GW300653X 0.52 0.45 0.485 0.035 
JOJ-G3 GW695874X -1.08 0.01 -0.535 0.545 
JOJ-G4 GW575533A 1.31 -0.2 0.555 0.755 
JOJ-G5 SB-657836-AAA -2.54 -0.61 -1.575 0.965 
JOJ-G6 GW807930X 1.98 1.81 1.895 0.085 
JOJ-G7 GSK943949A -1.1 -1.77 -1.435 0.335 
JOJ-G8 GW659386A 2.33 3.11 2.72 0.39 
JOJ-G9 GSK1511931A -0.17 -0.1 -0.135 0.035 
JOJ-G10 GSK969786A 1.54 1.76 1.65 0.11 
JOJ-H1 GW568326X -2.48 -0.07 -1.275 1.205 
JOJ-H2 GW861893X 1.42 1.89 1.655 0.235 
JOJ-H3 GW275944X 2.5 1.23 1.865 0.635 
JOJ-H4 GW278681X 0.19 -0.58 -0.195 0.385 
JOJ-H5 SB-711237 -0.15 1.12 0.485 0.635 
JOJ-H6 GW305178X 0.1 1.6 0.85 0.75 
JOJ-H7 GW445017X -0.06 -0.61 -0.335 0.275 
JOJ-H8 GW440139B -0.65 -0.52 -0.585 0.065 
JOJ-H9 GW651576X -0.19 -0.55 -0.37 0.18 
JOJ-H10 GW566221B 1.96 1.44 1.7 0.26 
JOK-A1 GSK182497A 1.21 1.4 1.305 0.095 
JOK-A2 GW778894X -0.83 -0.52 -0.675 0.155 
JOK-A3 SB-220455 -1.1 -1.4 -1.25 0.15 
JOK-A4 GW429374A -0.16 0.05 -0.055 0.105 
JOK-A5 GW784307A -0.54 -0.52 -0.53 0.01 
JOK-B1 GW781673X -1.53 -0.99 -1.26 0.27 
JOK-B2 SB-592602 -1.13 -0.7 -0.915 0.215 
JOK-B3 SB-278539 -1.25 -1.24 -1.245 0.005 
JOK-B4 GSK2213727A -0.73 -0.77 -0.75 0.02 
JOK-B5 GW576484X 1.97 2.06 2.015 0.045 
JOK-C1 GSK238583A -1.63 -1.19 -1.41 0.22 
JOK-C2 GSK1392956A -0.89 -1.23 -1.06 0.17 
JOK-C3 SB-437013 -1.59 -1.55 -1.57 0.02 
JOK-C4 SB-242717 -0.72 -0.91 -0.815 0.095 
JOK-D1 GW827105X 1.94 2.08 2.01 0.07 
JOK-D2 GW830365A -1.76 -0.93 -1.345 0.415 
JOK-D3 GSK317354A -0.48 -0.86 -0.67 0.19 
JOK-D4 SB-742864 -0.93 -0.88 -0.905 0.025 
JOK-E1 GW441756X -1.97 -1.17 -1.57 0.4 
JOK-E2 GR105659X -1.04 -1.13 -1.085 0.045 
JOK-E3 SB-735465 -1.06 -0.99 -1.025 0.035 
JOK-E4 GW806742X 2.59 2.69 2.64 0.05 
JOK-F1 GW589933X -0.75 -1.04 -0.895 0.145 
JOK-F2 SB-750140 -0.8 -0.92 -0.86 0.06 
JOK-F3 GW549390X -0.08 0.29 0.105 0.185 
JOK-F4 GW458344A -1.7 -1.26 -1.48 0.22 
JOK-G1 GW810576X -1.23 -0.69 -0.96 0.27 
JOK-G2 GW772405X -0.13 0.62 0.245 0.375 
JOK-G3 GW282974A -0.64 -0.2 -0.42 0.22 
JOK-G4 SB-431533 -0.37 -0.8 -0.585 0.215 
JOK-H1 GW853606X 0.82 0.72 0.77 0.05 
JOK-H2 SB-732941 -0.67 -0.83 -0.75 0.08 
JOK-H3 GW581744X -1.13 -0.58 -0.855 0.275 
JOK-H4 SB-221466 -0.53 -0.41 -0.47 0.06 
JOI-A1 GW673715X 1.75 2.32 2.035 0.285 
JOI-A2 GW811761X 1.02 -0.2 0.41 0.61 
JOI-A3 GW680975X 0.89 -0.02 0.435 0.455 
JOI-A4 GSK605714A 0.88 0.3 0.59 0.29 
JOI-A5 GW782612X -0.01 0.37 0.18 0.19 
JOI-B1 GSK192082A 2.74 1.72 2.23 0.51 
JOI-B2 SB-707548-A 4.01 3.55 3.78 0.23 
JOI-B3 SB-285234-W 0.81 -0.27 0.27 0.54 
JOI-B4 GR269666A -0.27 0.14 -0.065 0.205 
JOI-B5 GW559768X 0.7 0.38 0.54 0.16 
JOI-C1 SB-675259-M -0.32 -0.21 -0.265 0.055 
JOI-C2 GSK718429A 3.26 2.35 2.805 0.455 
JOI-C3 GW572738X 0.9 -0.11 0.395 0.505 
JOI-C4 GW621431X 0.64 -0.09 0.275 0.365 
JOI-C5 GW416981X 0.97 0.39 0.68 0.29 
JOI-D1 GSK237701A 0.54 -1.87 -0.665 1.205 
JOI-D2 GW567808A 2.72 2.37 2.545 0.175 
JOI-D3 GSK605714A 0.76 -0.01 0.375 0.385 
JOI-D4 GW561436X 0.78 -0.04 0.37 0.41 
JOI-D5 GW607117X 0.61 0.7 0.655 0.045 
JOI-E1 GSK978744A 0.64 -0.54 0.05 0.59 
JOI-E2 SB-744941 0.65 0.27 0.46 0.19 
JOI-E3 GW574782A 2.94 2.33 2.635 0.305 
JOI-E4 GW575808A 0.72 0.75 0.735 0.015 
JOI-E5 GW654652X 0.57 0.21 0.39 0.18 
JOI-F1 GW513184X 2.98 2.77 2.875 0.105 
JOI-F2 GW622055X 0.96 0.35 0.655 0.305 
JOI-F3 GW589961A 4.23 2.87 3.55 0.68 
JOI-F4 GW569293X 0.64 -0.06 0.29 0.35 
JOI-F5 GSK466317A 0.76 0.67 0.715 0.045 
JOI-G1 GW682841X 0.65 0.22 0.435 0.215 
JOI-G2 GSK1713088A 2.95 2.58 2.765 0.185 
JOI-G3 GW819230X 0.9 0.21 0.555 0.345 
JOI-G4 GW769076X 1.03 0.33 0.68 0.35 
JOI-G5 GW276655X 0.99 0.68 0.835 0.155 
JOI-H1 GW770249A 4.06 3.13 3.595 0.465 
JOI-H2 SB-242721 1.08 -0.14 0.47 0.61 
JOI-H3 GW642138X 3.15 2.45 2.8 0.35 
JOI-H4 GW820759X 0.76 0.5 0.63 0.13 
JOI-H5 GW819077X 1.3 1.52 1.41 0.11 
JOI-A6 GW680191X -0.44 -0.29 -0.365 0.075 
JOI-A7 GW583373A 1.12 1.14 1.13 0.01 
JOI-A8 GW335962X -0.12 -0.73 -0.425 0.305 
JOI-A9 GW301784X -0.7 -0.01 -0.355 0.345 
JOI-A10 GW824645A -0.05 0.41 0.18 0.23 
JOI-B6 GSK554170A -3.58 -0.21 -1.895 1.685 
JOI-B7 GSK1220512A 0.01 0.48 0.245 0.235 
JOI-B8 SB-253226 -0.19 -0.65 -0.42 0.23 
JOI-B9 GW282536X -0.12 -0.09 -0.105 0.015 
JOI-B10 GI98581X -0.07 0.53 0.23 0.3 
JOI-C6 GSK579289A -0.57 -0.5 -0.535 0.035 
JOI-C7 GW779439X 0.79 0.87 0.83 0.04 
JOI-C8 GW734508X 0.37 -0.46 -0.045 0.415 
JOI-C9 GW852849X -0.59 -0.47 -0.53 0.06 
JOI-C10 GW683134A 3.66 3.6 3.63 0.03 
JOI-D6 GW576924A 1.11 1.35 1.23 0.12 
JOI-D7 GW771127A 0.07 -0.15 -0.04 0.11 
JOI-D8 SB-210313 0.51 -0.6 -0.045 0.555 
JOI-D9 GW580496A 2.21 2.11 2.16 0.05 
JOI-D10 GSK2219385A -1.72 0.37 -0.675 1.045 
JOI-E6 GW633459A 0.75 0.38 0.565 0.185 
JOI-E7 GW795493X 2.14 3.26 2.7 0.56 
JOI-E8 GSK614526A -0.2 -0.5 -0.35 0.15 
JOI-E9 GW568377B -0.34 -0.02 -0.18 0.16 
JOI-E10 GW305074X 2.55 1.29 1.92 0.63 
JOI-F6 GSK466314A -0.16 -0.4 -0.28 0.12 
JOI-F7 SB-250715 -1.93 -0.42 -1.175 0.755 
JOI-F8 GSK1007102B -0.47 -1.07 -0.77 0.3 
JOI-F9 GW693917X 3.12 4.37 3.745 0.625 
JOI-F10 GSK2110236A 0.07 0.78 0.425 0.355 
JOI-G6 GW615311X 0.51 0.64 0.575 0.065 
JOI-G7 SB-284847-BT -0.18 -0.15 -0.165 0.015 
JOI-G8 GSK2220400A 0.26 -0.29 -0.015 0.275 
JOI-G9 GSK635416A -0.22 0.1 -0.06 0.16 
JOI-G10 SB-251527 -0.04 0.47 0.215 0.255 
JOI-H6 GW621823A 0.69 0.67 0.68 0.01 
JOI-H7 SB-254169 -0.05 0.07 0.01 0.06 
JOI-H8 SB-610251-B 0.84 0.8 0.82 0.02 
JOI-H9 SB-693162 -0.26 -0.11 -0.185 0.075 
JOI-H10 GW701427A 0.55 1.14 0.845 0.295 
JOH-A1 GW809885X -0.07 0.72 0.325 0.395 
JOH-A2 GW678313X -0.31 0.32 0.005 0.315 
JOH-A3 GW782912X -0.99 -0.18 -0.585 0.405 
JOH-A4 GW694234A 2.52 3.93 3.225 0.705 
JOH-A5 GW432441X -0.41 -0.35 -0.38 0.03 
JOH-A6 SB-251505 0.06 -0.14 -0.04 0.1 
JOH-A7 GW683109X -0.12 -0.04 -0.08 0.04 
JOH-A8 SB-735467 1.06 -0.36 0.35 0.71 
JOH-A9 GW785404X 0.87 -0.46 0.205 0.665 
JOH-A10 GW743024X 0.61 0.15 0.38 0.23 
JOH-B1 GW572401X -0.88 0.23 -0.325 0.555 
JOH-B2 GW280670X -0.55 0.17 -0.19 0.36 
JOH-B3 GW407323A 1.1 0.26 0.68 0.42 
JOH-B4 GW282449A -0.87 -0.24 -0.555 0.315 
JOH-B5 SB-347804 -0.07 0.75 0.34 0.41 
JOH-B6 SB-242718 0.12 -0.15 -0.015 0.135 
JOH-B7 GW616030X 1.59 -0.44 0.575 1.015 
JOH-B8 SB-358518 -0.26 -0.07 -0.165 0.095 
JOH-B9 SB-737198 -0.37 -0.41 -0.39 0.02 
JOH-B10 GSK994854A 0.81 0.54 0.675 0.135 
JOH-C1 GW406731X -0.95 -0.03 -0.49 0.46 
JOH-C2 GW279320X -1.07 0.22 -0.425 0.645 
JOH-C3 SB-698596-AC -0.59 0.16 -0.215 0.375 
JOH-C4 GW794607X -0.78 0.42 -0.18 0.6 
JOH-C5 SB-476429-A -1.64 -0.86 -1.25 0.39 
JOH-C6 GW817394X -0.34 0.85 0.255 0.595 
JOH-C7 GW693881A 4.7 4.61 4.655 0.045 
JOH-C8 SB-772077-B -0.58 -0.23 -0.405 0.175 
JOH-C9 SB-431542-A 0.16 0.51 0.335 0.175 
JOH-C10 GSK238063A 1.22 1.63 1.425 0.205 
JOH-D1 GW780056X -0.86 -0.01 -0.435 0.425 
JOH-D2 GW811168X -0.46 1.35 0.445 0.905 
JOH-D3 GW659893X 3.96 3.72 3.84 0.12 
JOH-D4 GW829874X -0.62 0.51 -0.055 0.565 
JOH-D5 GSK270822A -0.77 0.16 -0.305 0.465 
JOH-D6 GW396574X 1.36 1.57 1.465 0.105 
JOH-D7 SB-736302 -0.37 -0.17 -0.27 0.1 
JOH-D8 GSK269962B 0.38 0.87 0.625 0.245 
JOH-D9 GW632580X 0 0.13 0.065 0.065 
JOH-D10 GSK312948A 0.12 -0.11 0.005 0.115 
JOH-E1 GSK248233A -0.09 -0.5 -0.295 0.205 
JOH-E2 GW442130X -0.35 0.48 0.065 0.415 
JOH-E3 GW693481X -1.1 0.25 -0.425 0.675 
JOH-E4 GW679410X -1.21 0.43 -0.39 0.82 
JOH-E5 GW805758X -0.31 0.99 0.34 0.65 
JOH-E6 GW458787A 0.84 0.98 0.91 0.07 
JOH-E7 GW830900A -0.27 0.41 0.07 0.34 
JOH-E8 GW445014X -1.29 -0.41 -0.85 0.44 
JOH-E9 SB-725317 0.05 0.43 0.24 0.19 
JOH-E10 GW459057A 0.4 0.2 0.3 0.1 
JOH-F1 GW683768X -0.43 0.23 -0.1 0.33 
JOH-F2 GW275616X -0.88 0.23 -0.325 0.555 
JOH-F3 GW642125X -0.41 0.57 0.08 0.49 
JOH-F4 GW300660X -0.66 0.67 0.005 0.665 
JOH-F5 GW549034X -1.03 0.09 -0.47 0.56 
JOH-F6 GW708336X -0.66 0.28 -0.19 0.47 
JOH-F7 GW782907X -1.07 0.7 -0.185 0.885 
JOH-F8 SB-743899 -0.69 -0.23 -0.46 0.23 
JOH-F9 GSK980961A -0.74 0.22 -0.26 0.48 
JOH-F10 SB-590885-R 0.15 0.02 0.085 0.065 
JOH-G1 GSK949675A -1.61 -1.11 -1.36 0.25 
JOH-G2 GW786460X -1.42 0.43 -0.495 0.925 
JOH-G3 GW876790X -1.06 0.49 -0.285 0.775 
JOH-G4 GW427984X -0.74 0.3 -0.22 0.52 
JOH-G5 GSK2186269A -1.79 -1.53 -1.66 0.13 
JOH-G6 GW684626B -0.58 0.79 0.105 0.685 
JOH-G7 GW806290X -0.25 -0.28 -0.265 0.015 
JOH-G8 GW445012X -1.94 -0.02 -0.98 0.96 
JOH-G9 GW711782X -0.32 0.47 0.075 0.395 
JOH-G10 GW576609A 0.92 1.03 0.975 0.055 
JOH-H1 GSK1819799A 0.28 0.78 0.53 0.25 
JOH-H2 GSK625137A -1.09 0.28 -0.405 0.685 
JOH-H3 GW801372X -1.25 0.66 -0.295 0.955 
JOH-H4 GSK317314A -2.1 0.14 -0.98 1.12 
JOH-H5 GW284372X 0.38 0.28 0.33 0.05 
JOH-H6 GW701032X -1.34 0.38 -0.48 0.86 
JOH-H7 SB-216385 -0.55 0.47 -0.04 0.51 
JOH-H8 GW439255X -0.51 0.95 0.22 0.73 
JOH-H9 GW618013X 0.44 0.76 0.6 0.16 
JOH-H10 GSK1326255A 2.16 2.18 2.17 0.01 
TRB2+ATP+EDTA  2.325 2.78 2.5525 0.2275 
      
 
